(NASDAQ: KYMR) Kymera Therapeutics's forecast annual revenue growth rate of 8.01% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 107.7%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 26.15%.
Kymera Therapeutics's revenue in 2025 is $43,734,000.On average, 25 Wall Street analysts forecast KYMR's revenue for 2025 to be $5,448,627,866, with the lowest KYMR revenue forecast at $3,074,238,026, and the highest KYMR revenue forecast at $11,103,893,337. On average, 25 Wall Street analysts forecast KYMR's revenue for 2026 to be $4,308,379,686, with the lowest KYMR revenue forecast at $0, and the highest KYMR revenue forecast at $10,198,774,577.
In 2027, KYMR is forecast to generate $4,164,409,683 in revenue, with the lowest revenue forecast at -$916,630,604 and the highest revenue forecast at $7,554,647,835.